Company intelligence / Profile preview

F2G ARQUITECTURA Y DISEÑO

United Kingdom

Ownership: Private
Development stage: Other

Overview

F2G is developing olorofim, the first in a new class of antifungals called orotomides. Olorofim targets dihydroorotate dehydrogenase to disrupt pyrimidine synthesis in fungi. The drug has completed a Phase 2b study for rare and resistant invasive fungal infections and is currently in late-stage development with an ongoing Phase 3 trial comparing it to AmBisome. Olorofim has orphan drug status for invasive aspergillosis and scedosporiosis. The company is preparing for regulatory resubmission after the FDA requested additional data; no new clinical data are required, but updated historical control data are being compiled[4][6].

Therapeutic areas: Infectious Diseases
Modalities: Small molecule
Industry: Biotech

Partnerships

Shionogi Co., Ltd.

Beyond the preview

Go deeper on F2G ARQUITECTURA Y DISEÑO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on F2G ARQUITECTURA Y DISEÑO.

Explore the full profile